Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
In patients being treated for heart attack, complete revascularisation of all significantly blocked arteries leads to better outcomes compared to a strategy of unblocking just the “culprit” artery responsible for the heart attack, according to a new study presented today at ESC Congress 2014.
BARCELONA, Spain – Monday 1 September: In patients being treated for heart attack, complete revascularisation of all significantly blocked arteries leads to better outcomes compared to a strategy of unblocking just the “culprit” artery responsible for the heart attack, according to a new study presented today at ESC Congress 2014.Results of the Complete versus Lesion only PRimary-PCI Trial (CvLPRIT), presented as a congress Hot Line may be practice-changing when considered together with some other recent trials, said study investigator Anthony Gershlick, MD, from University Hospitals of Leicester NHS Trust, Glenfield Hospital, in Leicester, England.
“Until now there have been conflicting data regarding the optimal management of patients who, whilst undergoing primary percutaneous coronary intervention (P-PCI) after myocardial infarction (MI) are also found to have lesions in their non-infarct related artery (N-IRA),” noted Professor Gershlick.
“Current guidelines from ESC and AHA /ACC recommend treating the infarct-related artery (IRA) only, but the results of our study demonstrate a highly significant benefit with a strategy of complete revascularisation instead. These findings should suggest strongly that all lesions be treated before the patient is discharged,” he added.CvLPRIT included 296 heart attack patients who presented at seven UK interventional cardiology centres. Prior to treatment with P-PCI the patients were randomised to receive IRA-only revascularisation (n=146) or to have complete revascularisation of both the IRA as well as all N-IRAs (n=150) that were shown to be significantly blocked.For patients in the complete revascularisation group, the IRA was treated first, followed by the N-IRAs - preferably in the same sitting, but definitely during the same index hospital admission.The study found that one year after the procedure, patients in the complete revascularisation group had significantly better outcomes compared to those who had only their IRA revascularised, based on a composite endpoint of major adverse cardiac events (MACE) including: all-cause mortality, recurrent MI, heart failure and ischaemic-driven revascularisation. MACE occurred in 21.2% of the IRA-only arm versus 10.0% of the complete revascularisation group (hazard ratio [HR] 0.45; p=0.009), and the difference between the two groups was seen early (p=0.055 at 30 days). Not surprisingly, procedure time and contrast volume load were significantly higher in the complete revascularisation group compared to the IRA-only group (55 vs. 41 mins, p< 0.0001; and 250 vs. 190 mls, p< 0.0001, respectively), but despite this, the complete revascularisation patients had no increase in stroke, major bleeding or contrast-induced nephropathy, said Professor Gershlick. The CvLPRIT results correlate strongly with those of the earlier Preventive Angioplasty in Myocardial Infarction (PRAMI) Trial, which was presented during last year’s ESC Hot Line session.
“The PRAMI trial reported clear clinical benefit in treating both IRA and N-IRAs at the index P-PCI, but there was some criticism of the trial design,” said Professor Gershlick. “As a result, PRAMI has not led to widespread changes in clinical practice, with IRA-only revascularisation at P-PCI remaining by far the more common practice.”
However, he said the results of CvLPRIT reinforce the PRAMI results and strengthen the argument for a strategy of complete revascularisation at the time of a patient’s index hospital admission.
“The early separation of the curves in CvLPRIT suggests a delayed staged out-patient complete strategy may not be as effective,” he added.
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2014The ESC Congress is currently the world's largest international congress in cardiovascular medicine. The spotlight of this year's event is “innovation and the heart”. ESC Congress 2014 takes place from 30 August to 3 September at the Fira Gran Via in Barcelona, Spain. For more information on ESC Congress 2014 contact the ESC Press Office.To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2014. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.SOURCES OF FUNDING: The sponsor was the University Hospitals of Leicester NHS Trust. The main study was funded by the British Heart Foundation, with the CMR sub-study supported by the National Institute of Health Research. DISCLOSURES: Dr. Gershlick reports advisory board/meeting travel assistance/ lecture bureau: Medtronic Corp, Boston Scientific, Abbott vascular, Daiichi Sankyo, Medicines Company.
© 2017 European Society of Cardiology. All rights reserved